The past years, novel targeted therapies including fms-like tyrosine kinase 3 (FLT3) inhibitors and isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) inhibitors were incorporated into the therapeutic landscape of AML [3]. Here, FLT3 is linked to acute myeloid leukemia.